We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
206 result(s) found, displaying 1 to 10
-
Prescription medicine registrationActive ingredients: normal immunoglobulin.
-
Australian public assessment report (AusPar)Fruzaqla (fruquintinib) is approved for the treatment of adult patients with metastatic colorectal cancer (mCRC).
-
Apr-2025Prescription medicine evaluationActive ingredient: dengue virus serotype 1, dengue virus serotype 2, dengue virus serotype 3, dengue virus serotype 4.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for FRUZAQLA fruquintinib 5 mg hard capsule bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for FRUZAQLA fruquintinib 1 mg hard capsule bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Takeda Pharmaceuticals Australia Pty Ltd - Syringe, general-purpose.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TAKHZYRO lanadelumab 150 mg/1 mL solution for injection pre-filled syringe.
-
Jan-2025Prescription medicine evaluationActive ingredient: Brentuximab vedotin.
-
Jan-2025Prescription medicine evaluationActive ingredient: apadamtase alfa.
-
Prescription medicine registrationActive ingredients: fruquintinib.